Study
| EST. READ TIME 1 MIN.Canadian Pharmacare: Performance, Incentives, and Insurance
This paper discusses differences between provincial drug plans with respect to breadth of coverage and cost sharing between patients and taxpayers, and introduces two new measurements to describe how provincial Pharmacare plans perform as insurers and how generous they are to their beneficiaries. Finally, we compare these measurements with provinces' spending on their prescription benefit plans and consider which provinces get most value for their taxpayers' money.
-
John R. Graham
Senior Fellow, Fraser Institute (on-leave)John R. Graham is on-leave as a Senior Fellow with the Fraser Institute. He is currently serving with the U.S.Department of Health and Human Services (HHS) in Washington, DC. As well as the Fraser Institute he has held positions with the National Center for Policy Analysis, the Independent Institute, the Mackinac Center for Public Policy and the Pacific Research Foundation. Graham served as Vice-President of AdvaMed, the Advanced Medical Technology Association, until June 2013. Previously, he was the Director of Health Care Studies at The Pacific Research Institute in San Francisco, California from May 2005 through July 2012. He is also the former Director of Health & Pharmaceutical Studies at the Fraser Institute. He was an infantry officer in the Canadian Army in Canada, Cyprus, and Germany. Graham served on the institutional sales and trading teams of Goldman Sachs in Frankfurt, Germany and Kidder, Peabody in London, England.Graham received his M.B.A. from the London Business School (England) and his B.A. (with Honours) in Economics & Commerce from the Royal Military College of Canada. He is a Chartered Alternative Investment Analyst (CAIA Charterholder) and is an affiliate member of the CFA Society of Washington, DC, having completed all three levels of the CFA (Chartered Financial Analyst) program.… Read more -
Tanya Tabler
Tanya Tabler is a pharmacy student at the University of Alberta and worked as an intern at The Fraser Institute in pharmaceutical policy research during 2002 and 2003.